ES544769A0 - Procedimiento para la obtencion de nuevos compuestos este- roides - Google Patents

Procedimiento para la obtencion de nuevos compuestos este- roides

Info

Publication number
ES544769A0
ES544769A0 ES544769A ES544769A ES544769A0 ES 544769 A0 ES544769 A0 ES 544769A0 ES 544769 A ES544769 A ES 544769A ES 544769 A ES544769 A ES 544769A ES 544769 A0 ES544769 A0 ES 544769A0
Authority
ES
Spain
Prior art keywords
procedure
obtaining
new sterile
sterile compounds
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES544769A
Other languages
English (en)
Other versions
ES8705460A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy AG filed Critical Ciba Geigy AG
Publication of ES8705460A1 publication Critical patent/ES8705460A1/es
Publication of ES544769A0 publication Critical patent/ES544769A0/es
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J1/00Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003Androstane derivatives
    • C07J1/0011Androstane derivatives substituted in position 17 by a keto group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J13/00Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/005Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J21/00Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J21/00Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/001Lactones
    • C07J21/003Lactones at position 17
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J21/00Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005Ketals
    • C07J21/008Ketals at position 17
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J5/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J53/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002Carbocyclic rings fused
    • C07J53/0043 membered carbocyclic rings
    • C07J53/0073 membered carbocyclic rings in position 6-7
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J53/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002Carbocyclic rings fused
    • C07J53/0043 membered carbocyclic rings
    • C07J53/0083 membered carbocyclic rings in position 15/16
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J71/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005Oxygen-containing hetero ring
    • C07J71/001Oxiranes
    • C07J71/0015Oxiranes at position 9(11)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ES544769A 1983-04-13 1985-07-01 Procedimiento para la obtencion de nuevos compuestos este- roides Expired ES8705460A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH198183 1983-04-13

Publications (2)

Publication Number Publication Date
ES8705460A1 ES8705460A1 (es) 1987-05-01
ES544769A0 true ES544769A0 (es) 1987-05-01

Family

ID=4223123

Family Applications (4)

Application Number Title Priority Date Filing Date
ES531517A Expired ES8602846A1 (es) 1983-04-13 1984-04-11 Procedimiento para la obtencion de nuevos compuestos esteroides
ES544770A Expired ES8705461A1 (es) 1983-04-13 1985-07-01 Procedimiento para la obtencion de nuevos compuestos este- roides
ES544768A Expired ES8705459A1 (es) 1983-04-13 1985-07-01 Procedimiento para la obtencion de nuevos compuestos este- roides
ES544769A Expired ES8705460A1 (es) 1983-04-13 1985-07-01 Procedimiento para la obtencion de nuevos compuestos este- roides

Family Applications Before (3)

Application Number Title Priority Date Filing Date
ES531517A Expired ES8602846A1 (es) 1983-04-13 1984-04-11 Procedimiento para la obtencion de nuevos compuestos esteroides
ES544770A Expired ES8705461A1 (es) 1983-04-13 1985-07-01 Procedimiento para la obtencion de nuevos compuestos este- roides
ES544768A Expired ES8705459A1 (es) 1983-04-13 1985-07-01 Procedimiento para la obtencion de nuevos compuestos este- roides

Country Status (23)

Country Link
US (1) US4559332A (es)
EP (1) EP0122232B1 (es)
JP (1) JPS59231100A (es)
AR (4) AR241918A1 (es)
AT (1) ATE39256T1 (es)
AU (1) AU565017B2 (es)
CA (1) CA1220781A (es)
DD (2) DD233375A5 (es)
DE (2) DE3475622D1 (es)
DK (1) DK163988C (es)
ES (4) ES8602846A1 (es)
FI (1) FI77669C (es)
GR (1) GR81834B (es)
HU (1) HU191406B (es)
IE (1) IE57541B1 (es)
IL (1) IL71504A (es)
LU (1) LU91072I2 (es)
NL (1) NL300144I2 (es)
NO (1) NO159800C (es)
NZ (1) NZ207826A (es)
PH (1) PH19997A (es)
PT (1) PT78413B (es)
ZA (1) ZA842710B (es)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670551A (en) * 1984-06-21 1987-06-02 Ciba-Geigy Corporation Epoxy steroids
ATE164588T1 (de) * 1991-01-29 1998-04-15 Shionogi & Co Triterpenderivat
US6150347A (en) * 1992-04-21 2000-11-21 The Curators Of The University Of Missouri Use of aldosterone antagonists to inhibit myocardial fibrosis
US6245755B1 (en) 1992-04-21 2001-06-12 Curators Of The Unversity Of Missouri Use of aldosterone antagonists to inhibit myocardial fibrosis
JPH05329410A (ja) * 1992-05-29 1993-12-14 Sekisui Plastics Co Ltd マスキング材
US6262277B1 (en) 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6268392B1 (en) 1994-09-13 2001-07-31 G. D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
AU6039296A (en) * 1995-06-07 1996-12-30 G.D. Searle & Co. Method to treat cardiofibrosis with a combination therapy of an angiotensin ii antagonist and an epoxy-steroidal aldoste rone antagonist
WO1996040257A1 (en) * 1995-06-07 1996-12-19 G.D. Searle & Co. Epoxy-steroidal aldosterone antagonist and angiotensin ii antagonist combination therapy for treatment of congestive heart failure
US20020038021A1 (en) * 1995-12-11 2002-03-28 Barton Kathleen P. Eplerenone crystalline form exhibiting enhanced dissolution rate
US20020045746A1 (en) * 1995-12-11 2002-04-18 Barton Kathleen P. Eplerenone crystalline form
US20050267302A1 (en) * 1995-12-11 2005-12-01 G.D. Searle & Co. Eplerenone crystalline form exhibiting enhanced dissolution rate
ATE365171T1 (de) * 1995-12-11 2007-07-15 Searle Llc Verfahren zur herstellung einer epoxyverbindung
EP1167380A3 (en) * 1995-12-11 2004-12-08 G.D. Searle & Co. 11.alpha.-hydroxy-steroid-4,6-dien-3-one compounds and a process for their preparation
US20050159594A1 (en) * 1995-12-11 2005-07-21 Pharmacia Corporation Eplerenone crystal form exhibiting enhanced dissolution rate
AU747959B2 (en) * 1995-12-11 2002-05-30 G.D. Searle & Co. Processes and intermediates for the preparation of 9, 11-epoxy steroids
EP1223174A3 (en) * 1996-12-11 2005-03-16 G.D. Searle & Co. Processes for preparation of 3-keto-7alpha-alkoxycarbonyl-delta-4,5- steroids and intermediates useful therein
US6887991B1 (en) * 1996-12-11 2005-05-03 G. D. Searle & Company Processes for preparation of 9, 11-epoxy steroids and intermediates useful therein
NZ336004A (en) 1996-12-11 2001-04-27 G Process for preparation of 3-keto-7-alpha-alkoxycarbonyl substituted delta-4,5-steroid by reacting 4,5-dihydro-5,7-lactone steroid substrate in the presence of a base
WO1999062347A1 (fr) * 1998-05-29 1999-12-09 Kyowa Hakko Kogyo Co., Ltd. Procede de production d'assaisonnements liquides ayant la saveur de legumes marines dans une pate de son de riz salee
PL348198A1 (en) * 1998-11-06 2002-05-06 Searle & Co Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
WO2000038722A1 (en) 1998-12-23 2000-07-06 G.D. Searle & Co. COMBINATIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND HMG CoA REDUCTASE INHIBITORS FOR CARDIOVASCULAR INDICATIONS
IL143944A0 (en) * 1998-12-23 2002-04-21 Searle Llc Combinations for cardiovascular indications
ES2200587T3 (es) 1998-12-23 2004-03-01 G.D. Searle Llc Combinaciones de inhibidors del transporte de acidos biliares del ileon e inhibidores de la proteina de transferencia de colesteril ester para indicaciones cardiovasculares.
AU3103800A (en) 1998-12-23 2000-07-31 G.D. Searle Llc Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acidderivatives for cardiovascular indications
HUP0104793A2 (en) 1998-12-23 2002-06-29 Searle Llc Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indications
EP1340509A1 (en) 1998-12-23 2003-09-03 G.D. Searle LLC. Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications
MXPA01006470A (es) 1998-12-23 2003-06-06 Searle Llc Combinaciones de inhibidores de transporte de acido biliar ileal y agentes de secuentro de acido biliar para indicaciones cardiovasculares.
WO2000038723A1 (en) 1998-12-23 2000-07-06 G.D. Searle Llc Combinations of cholesteryl ester transfer protein inhibitors and bile acid sequestering agents for cardiovascular indications
US20030203884A1 (en) * 1999-11-09 2003-10-30 Pharmacia Corporation Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist
US20030096798A1 (en) * 1999-11-09 2003-05-22 Williams Gordon H. Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist
JP2003516414A (ja) * 1999-12-08 2003-05-13 ファルマシア コーポレイション より高い溶解速度を示すエプレレノン結晶形
CA2362845A1 (en) * 1999-12-08 2001-06-14 Pharmacia Corporation Eplerenone crystalline form
US20030083493A1 (en) * 1999-12-08 2003-05-01 Barton Kathleen P. Eplerenone drug substance having high phase purity
EP1527782A1 (en) * 1999-12-08 2005-05-04 Pharmacia Corporation Nanoparticulate eplerenone compositions
AU1756201A (en) * 1999-12-08 2001-06-18 Pharmacia Corporation Nanoparticulate eplerenone compositions
EP1505072A3 (en) * 1999-12-08 2006-06-21 Pharmacia Corporation Eplerenone crystalline form exhiniting enhanced dissolution rate
EP1286984A2 (en) 2000-03-10 2003-03-05 Pharmacia Corporation Method for the preparation of tetrahydrobenzothiepines
WO2001068096A2 (en) * 2000-03-10 2001-09-20 Pharmacia Corporation Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
WO2001087284A2 (en) * 2000-05-11 2001-11-22 Pharmacia Corporation Aldosterone antagonist composition for release during aldosterone acrophase
AU1604001A (en) * 2000-06-13 2001-12-24 Pharmacia Corp Use of an aldosterone antagonist for the treatment or prohpylaxis of aldosterone-mediated pathogenic effects
US6716829B2 (en) 2000-07-27 2004-04-06 Pharmacia Corporation Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
CA2415789A1 (en) * 2000-07-27 2002-02-07 Pharmacia Corporation Epoxy-steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure
DK1313485T3 (da) * 2000-08-28 2005-12-27 Pharmacia Corp Anvendelse af en aldosteronreceptorantagonist til forbedring af kognitiv funktion
CN1531590A (zh) * 2000-10-30 2004-09-22 赭曲霉11α-羟化酶和氧化还原酶
EP1343530B1 (en) * 2000-11-09 2007-08-08 AstraZeneca AB Oral pharmaceutical composition containing a block copolymer
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
US20040077625A1 (en) * 2001-07-25 2004-04-22 Tremont Samuel J. Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake
US20030220310A1 (en) * 2001-07-27 2003-11-27 Schuh Joseph R. Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
WO2003040127A1 (en) * 2001-11-02 2003-05-15 G.D. Searle Llc Novel mono- and di-fluorinated benzothiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (asbt) and taurocholate uptake
KR20040080439A (ko) * 2001-12-12 2004-09-18 파마시아 코포레이션 에폭시-스테로이드성 알도스테론 수용체 길항제에 의한안구 질환의 치료 방법
CA2471639A1 (en) 2002-01-17 2003-07-31 Pharmacia Corporation Novel alkyl/aryl hydroxy or keto thiepines.
AU2003222009A1 (en) * 2002-03-18 2003-10-08 Pharmacia Corporation Combination of an aldosterone receptor antagonist and nicotinic acid or a nicotinic acid derivative
EP1485105A1 (en) * 2002-03-18 2004-12-15 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a bile acid sequestering agent
EP1487540A2 (en) * 2002-03-20 2004-12-22 Pharmacia Corporation Storage stable eplerenone formulation
PL372460A1 (en) * 2002-03-22 2005-07-25 Pharmacia Corporation C-17 spirolactonization and 6,7 oxidation of steroids
US7235655B2 (en) * 2002-03-22 2007-06-26 Pharmacia & Upjohn Company Processes to prepare eplerenone
US20070066579A1 (en) * 2002-08-16 2007-03-22 White Michael J 5-androsten-3beta-ol steroid intermediates and processs for their preparation
JP2006507369A (ja) * 2002-08-16 2006-03-02 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 5−アンドロステン−3β−オールステロイド中間体およびそれらの製法
AU2003213807A1 (en) * 2002-11-06 2004-06-03 Pharmacia & Upjohn Company Llc Processes for preparing 7-carboxy substituted steroids
ATE354583T1 (de) * 2002-11-07 2007-03-15 Pharmacia & Upjohn Co Llc Verfahren zur herstellung c-7 substituierter 5- androstene
CL2004000545A1 (es) * 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul
CL2004000544A1 (es) * 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de una combinacion farmaceutica, de un antagonista del receptor de aldosterona y un inhibidor de endopeptidasa neutral, util para el tratamiento y prevencion de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopati
CL2004000574A1 (es) * 2003-03-21 2005-02-11 Pharmacia Corp Sa Organizada B Proceso para preparar un compuesto 17-espirolactona o la sal de lactona abierta por carbonilacion del correspondiente 17-alquenil o alquinil derivado, los intermediarios que se usan y su proceso de obtencion.
WO2004100871A2 (en) * 2003-05-09 2004-11-25 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a renin inhibitor
US20040265948A1 (en) * 2003-06-27 2004-12-30 White Michael Jon Microbial method for hydrolysis and oxidation of androst-5-ene and pregn-5-ene steroid esters
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
TW200602352A (en) * 2004-03-22 2006-01-16 Upjohn Co Improved process for the preparation of 9,11 epoxy steroids
US20070196471A1 (en) * 2004-04-02 2007-08-23 Thosar Shilpa S Micronized Eplerenone Compositions
US20050232957A1 (en) * 2004-04-14 2005-10-20 Katz Kenneth A Compositions and methods for moisturizing skin
CN1321128C (zh) * 2005-07-15 2007-06-13 浙江医药股份有限公司新昌制药厂 孕甾-4-烯-7,21-二甲酸,9,11-环氧-17-羟基-3-氧代,γ-内酯,甲酯,(7α,11α,17α)-的制备方法
WO2007025780A2 (en) * 2005-09-02 2007-03-08 Recordati Ireland Limited Aldosterone receptor antagonists
EP1842543A1 (en) 2006-04-05 2007-10-10 Speedel Pharma AG Pharmaceutical composition coprising an aldosterone synthase inhibitor and a mineralcorticoid receptor antagonist
US20070248665A1 (en) * 2006-04-24 2007-10-25 Sherman Bernard C Compositions comprising co-precipitate of eplerenone and a water-soluble excipient
DE102006028032A1 (de) * 2006-06-14 2007-12-20 Henkel Kgaa Aufhell- und/oder Färbemittel mit Nitrilen
CA2673419A1 (en) * 2006-12-21 2008-06-26 Alphapharm Pty Ltd Pharmaceutical composition
CA2582496A1 (en) * 2007-03-20 2008-09-20 Apotex Pharmachem Inc. Improved process for the preparation and purification of eplerenone
FR2917975B1 (fr) 2007-06-26 2009-10-16 Ceva Sante Animale Sa Compositions et traitement de l'insuffisance cardiaque chez les animaux mammiferes non humains
DE102008026793A1 (de) * 2008-06-02 2009-12-03 Bayer Schering Pharma Aktiengesellschaft C-Ring-substituierte Pregn-4-en-21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate
CN101863951B (zh) * 2009-04-15 2012-06-06 浙江省天台县奥锐特药业有限公司 依普利酮的制备方法
ME01923B (me) 2009-05-28 2015-05-20 Novartis Ag Supstituisani derivati aminopropionske kiseline kao inhibitori neprilizina
ES2582395T3 (es) 2009-05-28 2016-09-12 Novartis Ag Derivados aminobutíricos sustituidos como inhibidores de neprilisina
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
US10231976B2 (en) * 2010-02-08 2019-03-19 Prairie Pharmaceuticals LLC Methods for the use of progestogen as a glucocorticoid sensitizer
ES2641144T3 (es) 2010-05-10 2017-11-07 Inserm (Institut National De La Santé Et De La Recherche Medicale) Métodos y composiciones para el tratamiento de la acumulación de líquido en y/o bajo la retina
US9241944B2 (en) 2010-06-16 2016-01-26 Institut National De La Santé Et De La Recherche Médicale (Inserm) Methods and compositions for stimulating reepithelialisation during wound healing
TR201007653A2 (tr) 2010-09-20 2012-04-24 Bi̇lgi̇ç Mahmut Eplerenon içeren farmasötik kompozisyon
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
WO2012107513A1 (en) * 2011-02-10 2012-08-16 Crystal Pharma, S.A.U. Process for obtaining drospirenone
ITMI20121037A1 (it) * 2012-06-14 2013-12-15 Ind Chimica Srl Processo per la preparazione di nitrili utili come intermedi per la sintesi di molecole ad attivita' farmacologica
EP2956464B1 (en) 2013-02-14 2018-03-28 Novartis AG Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors
CN104262450A (zh) * 2014-09-19 2015-01-07 江苏嘉逸医药有限公司 依普利酮的制备及精制方法
ES2699923T3 (es) 2014-10-17 2019-02-13 Ind Chimica Srl Proceso para la preparación de 7alfa-(metoxicarbonil)-3-oxo-17alfa-pregn-4,9(11)-dien-21,17-carbolactona, un intermedio útil para la síntesis de moléculas con actividad farmacológica
WO2017055248A1 (en) 2015-09-28 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of heart failure
ES2846835T3 (es) 2015-10-13 2021-07-29 Inst Nat Sante Rech Med Métodos y composiciones farmacéuticas para el tratamiento de la neovascularización coroidea
CN105753930A (zh) * 2016-03-30 2016-07-13 北京万全德众医药生物技术有限公司 依普利酮的一种合成方法
WO2018019843A1 (en) 2016-07-26 2018-02-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
WO2023031277A1 (en) 2021-08-31 2023-03-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of ocular rosacea

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3095412A (en) * 1961-12-19 1963-06-25 Searle & Co 9alpha, 11alpha-epoxy and 11beta-chloro-9alpha-hydroxy 17alpha-(2-carboxyethyl)-17beta-hydroxyandrost-4-en-3-one gamma-lactones and delta1 and delta6 analogs
GB1041534A (en) * 1963-04-24 1966-09-07 Merck & Co Inc 20-spiroxane compounds
US3729491A (en) * 1970-06-15 1973-04-24 Searle & Co 3,5-dioxo-a-nor-b-homo steroidal spirolactones
GB1368006A (en) * 1972-08-24 1974-09-25 Searle & Co 4alpha,7alpha-carbonyl-5-cyano-17-hzydroxy-3-oxo-5beta,17alpha- pregnane-21-carboxylic acid ypsilon-lactone
US3849404A (en) * 1973-03-09 1974-11-19 Searle & Co Purification of 6,7-dihydro-17-hydroxy-3-oxo-3'h-cyclopropa(6,7)-17alpha-pregna-4,6-diene-21-carboxylic acid gamma-lactones
DE2652761C2 (de) * 1976-11-16 1985-11-21 Schering AG, 1000 Berlin und 4709 Bergkamen 15,16-Methylen-Spirolactone, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
DE2922500A1 (de) * 1979-05-31 1980-12-04 Schering Ag 6 beta .7 beta
DE3111951A1 (de) * 1981-03-23 1982-09-30 Schering Ag, 1000 Berlin Und 4619 Bergkamen 7(alpha)-alkoxycarbonyl-15ss-methylen-4-androstene, verfahren zu ihrer herstellung und verwendung als arzneimittel

Also Published As

Publication number Publication date
JPH0212479B2 (es) 1990-03-20
NZ207826A (en) 1986-07-11
DK189484A (da) 1984-10-14
ATE39256T1 (de) 1988-12-15
ES8705461A1 (es) 1987-05-01
NO159800C (no) 1989-02-08
LU91072I2 (fr) 2004-04-07
AR241918A1 (es) 1993-01-29
IL71504A0 (en) 1984-07-31
JPS59231100A (ja) 1984-12-25
FI841400A (fi) 1984-10-14
IL71504A (en) 1987-07-31
ES8705460A1 (es) 1987-05-01
AU2685384A (en) 1984-10-18
GR81834B (es) 1984-12-12
DK163988B (da) 1992-04-27
PT78413A (en) 1984-05-01
DE122004000012I2 (de) 2006-06-08
NO159800B (no) 1988-10-31
EP0122232B1 (de) 1988-12-14
AR242221A1 (es) 1993-03-31
PH19997A (en) 1986-08-28
DD251144A5 (de) 1987-11-04
ES531517A0 (es) 1985-12-01
NO841465L (no) 1984-10-15
DK163988C (da) 1992-09-21
IE57541B1 (en) 1992-10-07
FI77669B (fi) 1988-12-30
DE3475622D1 (en) 1989-01-19
ES8602846A1 (es) 1985-12-01
ES544768A0 (es) 1987-05-01
FI841400A0 (fi) 1984-04-09
DE122004000012I1 (de) 2012-05-16
AU565017B2 (en) 1987-09-03
HU191406B (en) 1987-02-27
IE840906L (en) 1984-10-13
AR242223A1 (es) 1993-03-31
AR242222A1 (es) 1993-03-31
ZA842710B (en) 1984-11-28
EP0122232A1 (de) 1984-10-17
US4559332A (en) 1985-12-17
DK189484D0 (da) 1984-04-12
FI77669C (fi) 1989-04-10
PT78413B (en) 1986-08-22
CA1220781A (en) 1987-04-21
ES8705459A1 (es) 1987-05-01
DD233375A5 (de) 1986-02-26
NL300144I1 (nl) 2004-06-01
NL300144I2 (nl) 2004-06-01
ES544770A0 (es) 1987-05-01

Similar Documents

Publication Publication Date Title
ES544768A0 (es) Procedimiento para la obtencion de nuevos compuestos este- roides
ES533260A0 (es) Procedimiento para la preparacion de 13a-alquilgonanos
ES532183A0 (es) Procedimiento para la preparacion de compuestos cefemicos
ES546945A0 (es) Procedimiento para la obtencion de compuestos carbonilicos
ES538621A0 (es) Procedimiento para la preparacion de fenolsulfonftaleinil-b-d-galactosidos
ES545154A0 (es) Procedimiento para la preparacion de n-piridilindoles
ES532957A0 (es) Procedimiento para la preparacion de sulfonilureas substituidas
ES554942A0 (es) Procedimiento para la obtencion de nuevos compuestos de piridazinio
ES537829A0 (es) Procedimiento para la obtencion de compuestos de eglina
ES535704A0 (es) Procedimiento para la obtencion de derivados de piridinio
MX156242A (es) Procedimiento para la preparacion de eter-sulfonatos
ES543624A0 (es) Procedimiento para la obtencion de nuevos compuestos de aralquiltriazol
ES535185A0 (es) Procedimiento para la preparacion de nuevas oxadiacinas
ES528114A0 (es) Procedimiento para la preparacion de hexanorbrassinolid-22-eteres
ES545611A0 (es) Procedimiento para la fabricacion de nuevos compuestos cina-moicos
ES532212A0 (es) Procedimiento para la obtencion de compuestos de 2-heterociclil-alquilo inferior-2-penem
ES535373A0 (es) Procedimiento para la preparacion de nuevas pirazolil- e isoxazolilsulfonilureas
ES533017A0 (es) Procedimiento para la obtencion de oxazolidinonas trisustituidas
ES527260A0 (es) Procedimiento para la obtencion de compuestos de 2-heterociclil-tio-alquilo inferior-penem
ES523098A0 (es) Procedimiento para la preparacion de compuestos de 4-azaftalida
ES539205A0 (es) Procedimiento para la obtencion de compuestos de 2-heterociclil-6-hidroxi-alquilo inferior-2-penem
ES531024A0 (es) Procedimiento para la preparacion de aminonitrilos
AR240908A1 (es) Procedimiento para la fabricacion de 2-halogeno- resorcinol
ES545962A0 (es) Procedimiento para la obtencion de compuestos de aminoal- quilpenem
AR240793A1 (es) Procedimiento para la preparacion de benzantrona

Legal Events

Date Code Title Description
PC1A Transfer granted
FD1A Patent lapsed

Effective date: 20070120